Viral Genetics Files 2009 3rd Quarter Consolidated Financials and Information Statement at Pinksheets.com

Tuesday, December 22, 2009 Corporate News
Email Print This Page Comment bookmark
Font : A-A+



SAN MARINO, Calif., Dec. 21 Biotechnology company Viral Genetics (Pink Sheets: VRAL) today announced that it filed an updated Information Statement including unaudited consolidated financial statements for the nine months ended September 30, 2009, as well as year-end statements for December 31, 2008 and 2007. This document is available in PDF form free of charge via the www.pinksheets.com website after entering the Company's ticker symbol and clicking "Filings". The Information Statement is a comprehensive disclosure document that describes the Company, its business, its products, risk factors, and financial performance.

About Viral Genetics Inc.

Headquartered in San Marino, Calif., Viral Genetics discovers and develops drug therapies to treat infectious, autoimmune, and immunological deficiency disorders using its thymus nuclear protein compound (TNP). The company has an exclusive license agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the company) to license technology developed that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. Viral Genetics has formed a wholly owned subsidiary, MetaCytoLytics, Inc., to advance a technology developed by University of Colorado Professor M. Karen Newell called "metabolic disruption technology" (MDT), which focuses on blocking a tumor cell's ability to generate energy from glucose or from fatty acids. Viral Genetics recently acquired exclusive rights to the metabolic disruption technology from the University of Vermont and the University of Colorado. Online at www.viralgenetics.com.

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of VGV-1 in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

Contact: Viral Genetics, Haig Keledjian, 626-334-5310

SOURCE Viral Genetics


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook